ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

サクビトリル

Sacubitril

HCID 9811834
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
149709-62-6
標準SMILES
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O
InChIKey
PYNXFZCZUAOOQC-UTKZUKDTSA-N
分子式
C24H29NO5
平均分子量
411.5 g/mol
単同位体質量
411.20457303

概要

Sacubitril is a member of biphenyls.

名称と識別子

優先名称
Sacubitril
IUPAC
4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid
現地名
サクビトリル
英語名
AHU-377
分子式
C24H29NO5
分子量
411.49

名称と別名

Sacubitril149709-62-6AHU-377AHU377sucabitrilAHU 377Sacubitrilo17ERJ0MKGI4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acidDTXSID20164370ENTRESTO COMPONENT SACUBITRIL(2R,4S)-5-(biphenyl-4-yl)-4-((3-carboxypropionyl)amino)-2-methylpentanoic acid ethyl ester
名称をさらに表示
4-(((2S,4R)-1-([1,1'-ビフェニル]-4-イル)-5-エトキシ-4-メチル-5-オキソペンタン-2-イル)アミノ)-4-オキソブタン酸サクビトリルサクビトリル (JAN)Sacubitril(AHU-377)(2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acidSacubitril APISacubitril, 10 mM in DMSOvalsartan/sacubitril Impurity 1AHU-37AHU-77LCZ697SACUBRITIL
3-{[(2S,4R)-1-{[1,1'-biphenyl]-4-yl}-5-ethoxy-4-methyl-5-oxopentan-2-yl]carbamoyl}propanoic acidsacubitrilum3-(((2S,4R)-1-((1,1'-biphenyl)-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)carbamoyl)propanoic acid4-(((2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl)amino)-4-oxobutanoic acidRefChem:884341DTXCID3086861810-278-24-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid

データベース識別子

CAS
149709-62-6
PubChem CID
9811834
DTXSID
DTXSID20164370
ChEMBL
CHEMBL3137301
ChEBI
CHEBI:134714
UNII
17ERJ0MKGI
EC Number
810-278-2
Nikkaji
J3.050.252C

物性

構造計算による物性補完中

XLogP
3.7
極性表面積
92.7 Ų
水素結合供与体数
2
水素結合受容体数
5
回転可能結合数
12
重原子数
30
形式電荷
0
複雑度
550

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; ACE Inhibitors; ACEIs

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

物理化学的性質

沸点
656.9 · 656.9±55.0 °C(Predicted)
比重(密度)
1.151 · 1.151±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
41.1 mg/mL · ≥41.1 mg/mL in DMSO; ≥21.45 mg/mL in H2O with ultrasonic; ≥26.85 mg/mL in EtOH with ultrasonic
外見
oil
酸解離定数(Pka)
4.72 · 4.72±0.10(Predicted)
色
colorless
InChIKey
PYNXFZCZUAOOQC-VNLCLAKNNA-N
SMILES
C(O)(=O)CCC(N[C@@H](C[C@@H](C)C(OCC)=O)CC1=CC=C(C2=CC=CC=C2)C=C1)=O |&1:7,9,r|

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 50% (1 of 2) of reports.

Warning

H317 (50%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P261, P264+P265, P272, P280, P302+P352, P305+P351+P338, P321, P333+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesSkin Sens. 1 (50%)

毒性情報

Hepatotoxicity · 1 件

The large prospective, placebo-controlled trials of sacubitril-valsartan in patients with heart failure usually did not mention or list ALT elevations or severe hepatic adverse events or deaths. In the FDA clinical review of data from these trials, elevations in ALT or AST were said to arise in 1.3% of patients on sacubitril-valsartan but a similar portion of those on enalapril [1.0%], and all elevations were judged to be unrelated to therapy and likely due to congestive liver disease due to heart failure. A single case of jaundice with aminotransferase elevations occurred, but in a patient who had stopped combination therapy because of worsening renal dysfunction and who was experiencing acute decompensated heart failure. Since approval and more widespread use of sacubitril-valsartan there have been at least two reports of acute liver injury attributed to its use. Both cases were relatively mild and resolved rapidly once the drug was stopped. Whether the injury was due to sacubitril or valsartan (or an interaction of both) was not clear. Valsartan, like other commonly used angiotensin receptor blockers, is known to be a rare cause of acute liver injury. The contribution of the underlying heart failure and possible congestive hepatopathy is also an issue. The reported cases did not have a liver biopsy and were not rechallenged with the drug which might have clarified the causality.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

ATC CodeC09DX04
Protein BindingSacubitril and it's metabolite, LBQ657 are highly bound to plasma protein (94-97%).
Pharmacodynamics · 1 件

n a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of sacubitril + valsartan (Entresto) resulted in a significant non-sustained increase in natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP compared to valsartan. In a 21-day study in HFrEF patients, it significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1. In clinical studies, this combination had no effect on QTc interval.

Mechanism of Action · 1 件

Sacubitril's active metabolite, LBQ657 inhibits neprilysin, a neutral endopeptidase that would typically cleave natiuretic peptides, which includes: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP). ANP and BNP are released under atrial and ventricle stress, which activate downstream receptors leading to vasodilation, natriuresis and diuresis. Under normal conditions, neprilysin breaks down other vasodilating peptides and also vasoconstrictors such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein. Therefore, the inhibition of neprilysin leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin II. (However, when combined with valsartan, would result in blocking of angiotensin II to its receptor, preventing the vasoconstrictive effects and resulting in a decrease in vascular resistance and blood pressure.) Cardiovascular and renal effects of sacubitril is a result of the increased levels of peptides that are normally degraded by neprilysin.

Biological Half-LifeThe half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours.
Metabolism/MetabolitesSacubitril is metabolized to LBQ657 by esterases. A low concentration (<10%) of a hydroxyl metabolite has been identified in plasma.
Absorption, Distribution and Excretion · 3 件

Peak plasma concentrations of sacubitril and it's metabolite, LBQ657 are reached in 0.5 hours and 2 hours respectively. Food does not clinically affect the systemic exposure of sacubitril or LBQ657. The oral bioavailability of sacubitril is >60%. It should be noted that the valsartan found in this combination is more bioavailable than other market available valsartan.

52% to 68% of sacubitril (primarily as the active metabolite LBQ657) is excreted in urine. 37% to 48% of sacubitril (primarily as LBQ657) is excreted in feces

103 L

上流・下流製品情報

上流原料

5-([1,1'-ビフェニル]-4-イル)-4-アミノ-2-メチルペンタン酸(2R,4S)-エチル HCL SALT(2R,4S)-2-メチル-4-アミノ-5-(4-ビフェニリル)ペンタン酸エチル(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoate(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acidEthyl (2R,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoate

下流製品

Sacubitril Sodium

関連反応

6 件
反応記録を作成
HRID 882539 の反応式
HRID 882539反応物として
HRID 1021055 の反応式
HRID 1021055反応物として
HRID 1469659 の反応式
HRID 1469659反応物として
HRID 1500441 の反応式
HRID 1500441反応物として
HRID 1641659 の反応式
HRID 1641659反応物として
HRID 2384081 の反応式
HRID 2384081反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート